Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-05
2009-08-25
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252130, C514S307000, C514S311000, C514S318000, C514S336000, C546S268100, C546S193000, C546S152000, C546S139000, C546S112000, C546S113000, C544S124000, C544S360000
Reexamination Certificate
active
07579347
ABSTRACT:
Compounds having the general structureand compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
REFERENCES:
patent: 3853561 (1974-12-01), Reichel et al.
patent: 3940422 (1976-02-01), Harita et al.
patent: 4011236 (1977-03-01), Grier
patent: 4536346 (1985-08-01), Shepherd et al.
patent: 4753934 (1988-06-01), Nickl et al.
patent: 4847275 (1989-07-01), Toda et al.
patent: 4908381 (1990-03-01), Greenwald et al.
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 5006548 (1991-04-01), Satoh et al.
patent: 5373019 (1994-12-01), Zilch et al.
patent: 5453421 (1995-09-01), Atwai et al.
patent: 5510367 (1996-04-01), Cugola et al.
patent: 5614521 (1997-03-01), Naruto et al.
patent: 5731324 (1998-03-01), Fisher et al.
patent: 5776930 (1998-07-01), Lynch et al.
patent: 5780487 (1998-07-01), Amer
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5919811 (1999-07-01), Conti et al.
patent: 6150385 (2000-11-01), Thaisrivongs et al.
patent: 6362210 (2002-03-01), Hauel et al.
patent: 6624184 (2003-09-01), Gu et al.
patent: 2003/0087922 (2003-05-01), Bethiel et al.
patent: 2005/0009815 (2005-01-01), DeVita et al.
patent: 0155871 (1985-09-01), None
patent: 0472116 (1992-02-01), None
patent: 63 154663 (1988-06-01), None
patent: 06179660 (1994-06-01), None
patent: WO 9507887 (1995-03-01), None
patent: WO 97/43241 (1997-11-01), None
patent: WO 00/06153 (2000-02-01), None
patent: WO 00/07993 (2000-02-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/68652 (2001-09-01), None
patent: WO 01/93682 (2001-12-01), None
patent: WO 02/079197 (2002-10-01), None
Fabio et al. J. Med. Chem. 40(6), 841-850, 1997.
Balsamini et al. J. Med. Chem. 41(6), 808-820, 1998.
Davis, et al. (2002) ‘The Vanilloid Receptor and Vanilloid Receptor-Like Genes: A Hot Topic Getting Hotter’,Celltransmissions18(2): 3-9.
Speranza et al. (2000) ‘The Michael Reaction ofN-Cinnamoylazoles with Phenols. A Simple Synthesis of 4-Arylchroman-2-ones and 1-Arylbenzo[ƒ]chroman-3-ones’Synthesis1:123-126.
Zabicky et al. (1961) ‘Studies in Absorption Spectra. The Arylacrylic System in the Infrared Region. Part II’,Bull. Res. Counc. of Israel10A:111-119.
Kibble, et al., Society for Neuroscience, “New Drugs 1” 4(12) 1319-1323 (2001).
Pau, et al., Il Farmaco, “Synthesis of 1-methyl-4-(N-aroyl)-piperidinamides with anti-inflammatory and analgesic activities” 53, 233-240 (1998).
Yeung, et al., J Med Chem., “Synthesis of N-(Carbonylamino)-1,2,3,6-tetrahydropyridines with Analgesic, Antiinflammatory ,and Hyperglycemic Activity” 25, 191-195 (1982).
Saraf, et al., Pyatigorsk Pharmaceutical Institute, “Synthesis and Antiallergic Activity in a Series of Cinnamic Acid” 598-602 (1991).
Bansal, et al., Eur J Med Chem., “Synthesis and anti-inflammatory activity of 1-acetyl-5-substitute daryl-3-(β-aminonaphthyl)-2-pyrazolines and β-(substituted aminoethyl amidonaphthaleses” 36, 81-92 (2001).
Kreutzberger, et al., Entzündungshemmende Wirkstoffe III. “(1,2)Synthese and entzündungshemmende Wirksamkeit aromatisch substituierter Benztriazole” 12, 665-667 (1975).
Rajan, et al., Bioorganic & Medicinal Chemistry Letters, “Synthesis and Evaluation of Caffeic Acid Amides as Antioxidants” 11, 215-217 (2001).
Peng, et al., The School of Pharmacy of the U of CA., “The Synthesis of Some 6-N-Substituted Amido Derivatives of 4,6-Diaminoquinaldine and a Study of their in vitro Antibacterial Activity” 78 3703-3708 (1956).
Valenzano, et al., Curr Med Chem., “Current perspectives on the therapeutic utility of VRIantagonists” 11(24) 3185 (2004).
Szallasi, et al., J of Medicinal Chem., “Vanilloid Receptor TRPVI Antagonists as the Next Generation of Painkillers. Are We Putting the Cart before the Horse?” 47(11) 2717-2723 (2004).
JP 60139646, CA 104: 33908 (1986).
Zimmerman, et al., Arch Pharm Med Chem., Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PFC) 329,7, pp. 371-376 (1996).
Lipinski, et al., J. Med Chem., “Pseudosymmetry and Bioisosterism in Biaryl Pyridyl Competitive Histamine H2-Receptor Antagonists” 28, pp. 1628-1636 (1985).
Abstract—Fusco, et al., Gazz Chim Ital., “phenyl-(4-phenyl-pyridin-2-yl)-amine” 98, p. 511 (1968).
Kuzuya, et al., Chem Pharm Bull, “Reactions of 1-Unsubstituted Tautomeric 2-Pyridones with Benzyne” 33, 6, pp. 2313-2322 (1985).
Abstract—Chem Abstracts Service, “4-(4-methoxyphenyl)-2-(1-naphthalenyloxy)” (1998).
Yeung, et al., J Med Chem., “Synthesis of N-(Carbonylamino)-1,2,3,6-tetrahydropyridines with Analgesic, Antiinflammatory, and Hyperglycemic Activity” 25, pp. 191-195 (1982).
Fourchard, et al., Arzneim ForschDrugRes, “Synthesis and Pharmacological Evaluation of (Indol-3-yl)alkylamides as Potent Analgesic Agents” 51, II, pp. 814-824 (2001).
Essawi, M., Dept of Organic Chemistry, “Synthesis and analgesic activity of N-aryl/arylalkyl 3-(1-pyrrolindinyl/piperidinyl)butyramides” 54, 8, pp. 575-579 (1999).
Menciu, et al., J. Med Chem., “New N-(Pyridin-4-yl)-(indol-3-yl)acetamides and Propanamides as Antiallergic Agents” 42, 4, pp. 638-648 (1999).
Hynes, et al., J. of Med Chem., “Synthesis and Evaluation of 6-Arylacetamido-2,4-diaminoquinazolines and Related Compounds as Folic Acid Antagonists” 18, 3, pp. 263-265 (1975).
Peng, et al., J. of the Am. Chem Soc., “The Synthesis of Some 6-N-Substituted Amido Derivatives of 4,6-Diaminoquinaldine and a Study of their in vitro Antibacterial Activity” 78, pp. 3703-3708 (1956).
Abstract—Renzi, et al., Gazz Chim Ital., 3-pyrrolidino-propionic acid-(2,3-dihydro-benzo[1,4]dionix-6-ylamide) 86, pp. 1362-1364 (1956).
Abstract—Bird, et al., J. Chem. Soc. Perkin Trans., “N,3-Diphenyl-3-(4-totyl)propionamid” 1 pp. 2664-2667 (1973).
Abstract—Hardman, J. Am. Chem. Soc., “3-(2-hydroxy-[1]naphthyl)-propionic acid-[1]naphthylamide” 70, p. 2119 (1948).
Abstract—Gaivoronskaya, et al., Pharm Chem J., “N-(1,2,5-trimethylpiperidyl-4)-propanilide” 18, 9 pp. 615-618 (1984).
Abstract—Knunjanz, et al., Acac Sci USSR Div Chem Sci., “3-Brom-3-phenyl-propionsaeure-(naphthyl-(2)-amid)” p. 494 (1960).
Abstract—Smith, Helv Chim Acta, 3-pyrrolidino-butyric acid-(4-chloro-anilide) 42, pp. 1764-1770 (1959).
Bo Yunxin Y.
Chakrabarti Partha P.
Chen Ning
Doherty Elizabeth M.
Fotsch Christopher H.
Amgen Inc.
Balasubramanian Venkataraman
Person Richard V.
LandOfFree
Vanilloid receptor ligands and their use in treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanilloid receptor ligands and their use in treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanilloid receptor ligands and their use in treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074164